Oncogene Inhibitor Global Market Report 2025

The oncogene inhibitor market size has grown strongly in recent years. It will grow from $39.68 billion in 2024 to $43.27 billion in 2025 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period is due to factors such as increased research on resistance mechanisms, the expansion of targeted therapies, heightened research efforts for lung cancer treatment, rising investment in KRAS and MYC inhibitors, and boosted funding and grants.

The oncogene inhibitor market size is expected to see strong growth in the next few years. It will grow to $60.36 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period is due to increased healthcare investments, the emphasis on tumor-agnostic treatments, rising use of targeted therapies, supportive regulatory and reimbursement frameworks, and the advancement of personalized medicine and companion diagnostics. Key trends expected during this period include the emergence of next-generation KRAS inhibitors, AI-powered drug discovery platforms, integration of real-time liquid biopsy, modulation of the tumor microenvironment, and the development of targeted nanoparticle-based drug delivery systems.

An increase in the prevalence of cancer is expected to propel the growth of the oncogene inhibitor market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. It is increasing due to unhealthy lifestyles, as habits such as smoking, poor diet, lack of exercise, and alcohol use weaken the body and promote the growth of cancerous cells. Oncogene inhibitors help combat cancer by targeting and blocking specific genes that drive cancer cell growth, thereby slowing or stopping tumor development and progression. For instance, in July 2024, according to a report published by Cancer Research UK, a UK-based charity, the average annual number of new melanoma skin cancer cases in the UK is expected to increase from approximately 20,800 in 2023-2025 to around 26,500 in 2038-2040. Therefore, an increase in the prevalence of cancer is driving the growth of the oncogene inhibitor market.

Major companies operating in the oncogene inhibitor market are focusing on developing innovative treatment options, such as novel functional genomic approaches, to enhance the precision and efficacy of cancer treatments. Novel functional genomic approaches refer to advanced methodologies that integrate various genomic, transcriptomic, and epigenomic data to understand gene functions and their roles in diseases such as cancer. For instance, in May 2024, Delphia Therapeutics, a US-based biotechnology company, introduced a novel approach called activation lethality to exploit cancer’s vulnerability to oncogene overactivation. Leading oncology drug developers Kevin Marks, Bill Sellers, and Mike Dillon have secured $67 million in funding to advance this strategy. Activation lethality targets the excessive activation of oncogenes, genes that, when mutated or highly expressed, can drive cancer development. Some cancer cells rely on this overactivation for survival, and by inducing lethal stress through targeted intervention, this approach selectively kills those cancer cells while sparing healthy ones.

In November 2023, Revolution Medicines Inc., a US-based biotech company, acquired EQRx for an undisclosed amount. Through this acquisition, EQRx benefits by aligning with a company that has a strong focus on developing RAS(ON) inhibitor drugs for RAS-driven cancers, potentially accelerating the development and commercialization of its oncology programs. Additionally, the acquisition offers EQRx greater access to resources, expertise, and infrastructure, enhancing its ability to advance innovative oncogene inhibitor therapies. EQRx Inc. is a US-based biotech company that offers oncogene inhibitors.

Major players in the oncogene inhibitor market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Mirati Therapeutics Inc., AstraZeneca PLC, Incyte Corporation, Blueprint Medicines Corporation, Astex Pharmaceuticals Inc., G1 Therapeutics Inc., Nurix Therapeutics Inc., GenFleet Therapeutics Co Ltd., Relay Therapeutics Inc.

North America was the largest region in the oncogene inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in oncogene inhibitor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the oncogene inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

An oncogene inhibitor is a type of therapeutic agent or drug developed to inhibit the function of oncogenes, which are genes capable of triggering cancer when they become overactive or mutated. These inhibitors specifically target the abnormal proteins that oncogenes produce, which are responsible for driving unregulated cell division and tumor growth. By impeding these proteins, oncogene inhibitors can help to reduce or halt the development of certain cancers.

Oncogene inhibitors are mainly available in two forms: oral and injectable. Oral medications are taken by mouth and typically come in forms such as pills, tablets, capsules, or liquid solutions. These are used across various drug categories, including biologics, small molecule drugs, and combination therapies. The key indications include breast cancer, ovarian cancer, lung cancer, pancreatic cancer, and others. These drugs are distributed through several channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and they are utilized by different end users such as hospitals, specialty clinics, and other healthcare facilities.

The oncogene inhibitor market research report is one of a series of new reports that provides oncogene inhibitor market statistics, including oncogene inhibitor industry global market size, regional shares, competitors with an oncogene inhibitor market share, oncogene inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the oncogene inhibitor industry. This oncogene inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oncogene inhibitor market consists of sales of imatinib, erlotinib, gefitinib, vemurafenib, dabrafenib, crizotinib, and ceritinib. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.